Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study

NCT01291836 · View on ClinicalTrials.gov ↗

Study Summary

AKINESIS is a clinical study to assess the utility of blood and urine NGAL tests in predicting worsening kidney function in patients who present with acute heart failure (AHF) and who are treated with diuretics. It is believed that rising NGAL levels in the blood and/or urine can predict acute kidney injury. It is also believed that patients who are admitted to the hospital with high NGAL levels in the blood/urine will have poorer outcomes.

Study Locations (13)

Other

  • Athens University Hospital Attikon — Athens
  • University Hospital Dublin — Dublin
  • Clinica Mediterranea — Naples
  • Monasterio Foundation for Medical Research and Public Health — Pisa
  • Hospital Clínico Universitario Valencia — Valencia

California

  • University of California San Diego Medical Center — San Diego
  • San Diego Veterans Administration Hospital — San Diego

Kansas

  • Kansas University Medical Center — Kansas City

Michigan

  • Henry Ford Health System — Detroit

New York

  • New York Methodist Hospital — Brooklyn

Virginia

  • Virginia Commonweath University Medical Center — Richmond

GZ Groningen

  • University of Groningen Medical Center — Groningen

Petersgraben

  • Universitätsspital Basel — Basel

Trial Details

FieldValue
Enrollment Target 930 participants
Start Date 2010-12
Est. Completion 2015-06

Sponsor

Alere San Diego

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01291836

The ClinicalTrials.gov registry entry for NCT01291836 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 930 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alere San Diego, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01291836 reports 13 study locations spanning 8 distinct geographic areas — top geographies include Other, California, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01291836 about?

NCT01291836 is a clinical study titled "Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study". AKINESIS is a clinical study to assess the utility of blood and urine NGAL tests in predicting worsening kidney function in patients who present with acute heart failure (AHF) and who are treated with diuretics. It is believed that rising NGAL levels in the blood and/or urine can predict acute kidne...

What is the current status of trial NCT01291836?

This trial is currently completed. The enrollment target is 930 participants. The study started on 2010-12. Estimated completion is 2015-06.

What conditions does trial NCT01291836 study?

This clinical trial studies the following conditions: Acute Kidney Injury, Acute Decompensated Heart Failure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT01291836?

This trial is sponsored by Alere San Diego, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01291836 being conducted?

This trial has 13 study locations across California, Kansas, Michigan, New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial